Business
Lexington Cardiovascular Health Monitor Performing as Designed with First Clinical Patients
Lexington Cardiovascular Health Monitor Performing as Designed with First Clinical Patients.
About this update from Lexington Biosciences Inc
[{"type":"text","content":"\n\n VANCOUVER, British Columbia, March 05, 2018 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to provide an early update of its clinical trial and patient enrollment. As previously announced, the Company’s HeartSentry device is undergoing clinical studies designed to measure the safety and effectiveness of the patented technology designed for cardiovascular health diagnosis.\n The team at San Francisco Bay-area Diablo Clinical Research, site of the investigative study has advised the Company that five patients have now been successfully enrolled and admitted to the program, and have undergone the first series of tests with HeartSentry. Under the expert leadership of Dr. Geoff Tison, M.D. M.P.H., initial results indicate the device is functioning as designed with quantifiable results.   Jonathan S. Maltz, Ph.D., Lexington’s lead researcher, Chief Scientific Advisor, and one of the driving forces behind the development of the HeartSentry technology notes, “I am really excited to report that the Gen-1 HeartSentry devices are working well. All the machines are functioning within their operational parameters and delivering excellent results, and the data is being collected as designed. After fifteen years of effort, it’s truly remarkable to watch our hard work undergoing rigorous examination in a clinical environment. I am watching events closely and at this point couldn’t be happier.” HeartSentry was designed as a diagnostic device offering a new approach to non-invasive measurement and monitoring of cardiovascular health by assessing the function of a patient’s vascular endothelium, the vital innermost lining of the cardiovascular system. The Company designed HeartSentry to be accurate, quick, and cost-effective, with the intent to position it to become the standard of care for cardiologists, general practitioners, and ultimately patients for first-line evaluation of cardiovascular health. Lexington’s President Eric Willis advises, “It has been gratifying to watch our first patients providing the researchers with the beginning of what we believe will become a wave of consistently replicable data in the days and weeks ahead. We have been a...